Compare MSBI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | OCS |
|---|---|---|
| Founded | 1881 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.4M | 732.4M |
| IPO Year | 2011 | 2022 |
| Metric | MSBI | OCS |
|---|---|---|
| Price | $32.59 | $7.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $33.25 | ★ $36.73 |
| AVG Volume (30 Days) | 128.6K | ★ 291.2K |
| Earning Date | 10-22-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.94 | N/A |
| Revenue Next Year | $0.71 | $365.20 |
| P/E Ratio | $20.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.24 | $7.11 |
| 52 Week High | $35.10 | $34.48 |
| Indicator | MSBI | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 24.99 |
| Support Level | $29.78 | N/A |
| Resistance Level | $33.84 | $13.49 |
| Average True Range (ATR) | 0.70 | 0.44 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 22.88 | 10.97 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.